



Express Mail No.: EL 477 035 735 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: *Palese et al.*

Application No.: 09/724,427

Art Unit: 1636

Filed: November 28, 2001

Examiner: To be assigned

For: RECOMBINANT NEGATIVE STRAND  
RNA VIRUS EXPRESSION SYSTEMS  
AND VACCINES

Atty Docket No.: 7682-053

**RESPONSE TO OFFICE COMMUNICATION**

Assistant Commissioner for Patents  
Washington, D.C. 20231

S I R:

In response to the outstanding Office communication mailed on November 23, 2001, please enter the following amendments and consider the remarks below. Applicants submit concurrently herewith: (1) a Petition for Extension of Time for two months from March 2, 2002 to and including May 2, 2002, accompanied by the appropriate fees; (2) a copy of the Office communication mailed on January 2, 2002; (3) a Submission of a Substitute Sequence Listing in paper form; (4) a Substitute Sequence Listing in computer-readable form; and (5) under separate Transmittal, a Statement under 37 C.F.R. § 1.825 affirming that the Substitute Sequence Listing and the computer-readable copy thereof are the same and do not include new matter.

Should any fee in addition to the fee accompanying the Petition for Extension of Time be due, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.

**IN THE SEQUENCE LISTING**

Please amend the sequence listing by entering the replacement sequence listing enclosed herewith pursuant to 37 C.F.R. § 1.825.

**REMARKS**

The Sequence Listing has been amended to conform with 37 C.F.R. § 1.823 with regard to the use of "n" in nucleotide sequences. No new matter is introduced by virtue of this amendment, and the amendment is fully supported by the Specification of the subject application and the claims as originally filed. Accordingly, Applicants kindly request that the present Substitute Sequence Listing be entered into the instant application.

Respectfully submitted,

Date April 19, 2002

by: *Jacqueline Benn* Reg. No. *43,492*  
*Laura A. Coruzzi* 30,742  
Laura A. Coruzzi (Reg. No.)

PENNIE & EDMONDS LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090

Enclosures



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/724,427 ✓	11/28/2000	Peter Palese	7682-053 ✓

20583  
PENNIE AND EDMONDS  
1155 AVENUE OF THE AMERICAS  
NEW YORK, NY 100362711

2428

CONFIRMATION NO. 7446

## FORMALITIES LETTER



\*OC0000000724840\*

Date Mailed: 01/02/2002

Seq. Listing: 3/2/02

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

